ELN Leukemias CMPD Contact  · 

Contact Persons in Project 9: Chronic myeloproliferative diseases (CMPD)

Created by: Hellenbrecht (ELIC) , generated 2006/03/14, last changed: 2008/06/04

Name	Initials	E-mail	Clinic	Country
Lead Participants
T. Barbui	BAR		Azienda Ospedaliera-Ospedali Riuniti di Bergamo	Italy
G. Barosi	BARO		IRCCS Policlinico S. Matteo	Italy
G. Finazzi	FIN		Azienda Ospedaliera-Ospedali Riuniti di Bergamo	Italy
J. Kiladjan	KIL			France
H.H. Pahl *	PAH		Universitätsklinikum Freiburg	Germany
Participants
G. Birgegard	BIRG		Uppsala Universitet	Sweden
H. Cario	CAR			Germany
N. Casadevall	CASA			France
F. Cervantes	CER		Hospital Clínic i Provincial de Barcelona	Spain
G. Finazzi	FIN			Italy
F. Frassoni	FRA		Azienda Ospedaliera Ospedale San Martino	Italy
H. Gisslinger	GIS		Medizinische Universität Wien	Austria
M. Griesshammer	GRIE		Universität Ulm	Germany
H. Hasselbalch	HASS		Odense University Hospital	Denmark
J.M. Hernandez	HERN			Spain
H.H. Kreipe	KRE		Medizinische Hochschule Hannover	Germany
M.C. Le Bousse-Kerdilès *	LEB		Institut National de la Santé et de la Recherche Médicale	France
E. Lengfelder *	LEN		Ruprecht-Karls-Universität	Germany
M.F: McMullin *	MCMU			UK
F. Passamonti	PASS			Italy
A. Rambaldi	RAMB		Azienda Ospedaliera-Ospedali Riuniti di Bergamo	Italy
T. Reilly	REIL		University of Sheffield	UK
A. Reiter	REIT		Ruprecht-Karls-Universität	Germany
C.R. Rinaldi	RINA			Italy
A. Schmitt-Gräff *	SCHG		Universitätsklinikum Freiburg	Germany
J. Thiele	THIE		Universität Köln	Germany
W. Vainchenker	VAIN			France
A. Vannucchi	VANN			Italy
S. Zweegman *	ZWE			Netherlands
* = Female Researcher

Lead Participants:

Prof.Dr. T. Barbui (Bergamo, Italy): Main research interests are CMPD‘s, acute leukemias and acquired thrombophilic disorders. He is appointed for integrating European cooperative groups in the framework of the European Hematology association (EHA). He chaired the European working group on CMPD.

Prof.Dr. G. Barosi (Pavia, Italy): Head of the Laboratory of Medical Informatics at the University Hospital of Pavia. He is expert in information science, clinical trial conduct, operational research, and in the management and clinics of patients with myelofibrosis with myeloid metaplasia (MMM). Chairman of the Italian Registry for MMM, International reputation for biology (CD34 phenotype in MMM) and treatment (Trials with Thalidomide and diagnostic criteria for MMM).

Prof.Dr. G. Finazzi (Bergamo, Italy): Head of the Department Hemostasis and Thrombosis, Ospedali Riuniti, Bergamo, Italy. Member of the Executive Committee, Federazione Italiana dei Centri per la Sorveglanza della Terapia Anticoagulante Oral (FCSA).

Prof.Dr. J. Kiladjan (, France):

Prof.Dr. H.H. Pahl (Freiburg, Germany): Center for Clinical Research, University Hospital Freiburg. She is a well recognized scientist in the field of CMPD. She was the first to describe the overexpression of PRV1 in PV and ET.

Participants:

Prof.Dr. G. Birgegard (Uppsala, Sweden): Department of Hematology, Center for Medicine, University Hospital, Uppsala. Chairman of the Nordic Group for Myeloproliferative Disorders (Nordic MPD Group) and Co-author of guidelines for treatment of MPD in Sweden. His research has focussed on erythropoiesis and the pathophysiology of polycythemia vera as well as erythropoietin pathophysiology and Epo treatment. He is the head investigator in the anagrelide treatment study performed by the Nordic MPD Group.

H. Cario (, Germany):

N. Casadevall (, France):

Prof.Dr. F. Cervantes (Barcelona, Spain):

G. Finazzi (, Italy):

Dr. F. Frassoni (Genova, Italy): Head Stem Cell Centre and Cellular Therapy, Department of Hemato-Oncology, Ospedale San Martino, Genova. Chairman of Acute Leukemia Working Party of the European Blood and Marrow Transplant Group. Longstanding experience in clinical and experimental hematopoetic stem cell transplantation. (HSCT). PI or Co-PI of several studies in the field of HSCT, Hematology and Plasticity of Stem Cells. Reviewer for major journals in the field of hematology and stem cell transplantation. Research interest: stem cell biology, leukemia, treatment of leukemia, hematopoietic stem cell transplantation.

Prof.Dr. H. Gisslinger (Vienna, Austria): University of Vienna, Department of Internal Medicine I, Division of Hematology and Blood Coagulation. He published the first description of the therapeutic effect of Interferon alpha on lowering of platelet counts in Ph-neg. CMPD and did several investigations on the effect and side effects as well as pathophysiological effects of interferon alpha in patients with CMPD.

PD Dr. M. Griesshammer (Ulm, Germany): Department of Hematology and Oncology, University of Ulm, Germany. Coordinator of the German National Network on „Myeloproliferative Disorders“ conducting studies on pathogenesis and treatment of these diseases.

Prof.Dr. H. Hasselbalch (Odense, Denmark): Diagnosis and treatment of myeloproliferative disorders. Member of the Nordic MPD study group.

J.M. Hernandez (, Spain):

Prof.Dr. H.H. Kreipe (Hannover, Germany): Professor of Pathology and Head of Department of Pathology Medizinische Hochschule Hannover. Hematopathology and Molecular Pathology.

Prof.Dr. M.C. Le Bousse-Kerdilès (Villejuif, France): Coordinator of the French INSERM clinical research network on MMM and is an active member of several professional societies in France and Europe. Director of Research at the National Institute of health and Medical Research (INSERM). The main topic of her research is the pathophysiology of myeloproliferative disorders. Results obtained within the framework of the French network gave new insight in the genesis of MMM and have been published in international journals.

PD Dr. E. Lengfelder (Heidelberg, Germany):

M.F: McMullin (, UK):

F. Passamonti (, Italy):

Prof.Dr. A. Rambaldi (Bergamo, Italy): Head of the Bone Marrow Transplantation Unit, Ospedali Riuniti Bergamo. Experience in clinical research on acute and chronic leukemias and lymphatic malignancies and hematopoietic stem cell transplantation. Molecular monitoring of minimal residual disease in Lymphoma and Leukemia.

Dr. T. Reilly (Sheffield, UK): Pathogenesis of idiopathic myelofibrosis. During the last ten years he has led a research team investigating the pathogenesis of idiopathic myelofibrosis and related disorders. Currently, they are investigating the role of c-fms, c-kit as well as characterizing the circulating stem cell compartment.

PD Dr. A. Reiter (Heidelberg, Germany): Klinikum Mannheim of the University of Heidelberg. Major interests in detection of MRD in CML and identification of molecular mechanisms leading to reciprocal translocations in CML, CML-related chronic myeloproliferative disorders and acute promyelocytic leukemia. Involved in the molecular cloning of several reciprocal translocations in chronic myeloproliferative disorders which disrupt genes encoding the tyrosine kinase receptors PDGFRA, PDGFRB, or FGFR1 respectively.

C.R. Rinaldi (, Italy):

Prof.Dr. A. Schmitt-Gräff (Freiburg, Germany): Institue of Pathology, University of Freiburg. Longstanding experience in evaluation of bone marrow biospsies in chronic myeloproliferative disorders.

Prof.Dr. J. Thiele (Cologne, Germany): Institute of Pathology, University of Cologne. Hematopathology (chronic myeloproliferative disorders-electron microscopy, immunohistochemistry, clinico-pathological studies).

W. Vainchenker (, France):

A. Vannucchi (, Italy):

S. Zweegman (, Netherlands):